Fuan Pharmaceutical (Group) (300194) Fundamentals 2026 — P/E 71.6x, Revenue Analysis | SniperIQ
Fuan Pharmaceutical (Group) (300194) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.4B, trading at ¥3.70 on the SHZ. This SniperIQ fundamentals page covers Fuan Pharmaceutical (Group)'s valuation (P/E 71.6x, P/B 1.0x), profitability (net margin 3.7%), revenue (¥1.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Fuan Pharmaceutical (Group)'s market cap?
Fuan Pharmaceutical (Group) (300194) has a market capitalization of approximately ¥4.4B, trading at ¥3.70 on the SHZ. Market cap moves with the live share price.
What is Fuan Pharmaceutical (Group)'s P/E ratio?
Fuan Pharmaceutical (Group)'s trailing twelve-month P/E ratio is 71.6x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Fuan Pharmaceutical (Group)?
Fuan Pharmaceutical (Group) runs a net profit margin of 3.7%, a gross margin of 35.7%, and an operating margin of -0.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fuan Pharmaceutical (Group) generate?
Fuan Pharmaceutical (Group) reported revenue of ¥1.7B for fiscal year 2025, with net income of ¥77M and earnings per share (EPS) of 0.0647. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fuan Pharmaceutical (Group) pay a dividend?
Fuan Pharmaceutical (Group) offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Fuan Pharmaceutical (Group) financially healthy?
Fuan Pharmaceutical (Group) carries a debt-to-equity ratio of 0.16x and a current ratio of 2.25x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fuan Pharmaceutical (Group) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fuan Pharmaceutical (Group) (300194) the key facts are: market cap ¥4.4B, P/E 71.6x, revenue ¥1.7B, 52-week range 3.24-5.48. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Fuan Pharmaceutical (Group)'s full fundamentals live
Get Fuan Pharmaceutical (Group)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.